International Clinical Trial: A phase 3 randomized double-blinded, placebo-controlled study of JNJ-78278343, T-Cell redirecting agent targeting Human Kallikrein 2 with best supportive care (BSC) versus placebo with BSC for metastatic castration-resistant prostate cancer_KLK2 comPAS_78278343PCR3001

Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (ISRCTN21855023) titled 'A phase 3 randomized double-blinded, placebo-controlled study of JNJ-78278343, T-Cell redirecting agent targeting Human Kallikrein 2 with best supportive care (BSC) versus placebo with BSC for metastatic castration-resistant prostate cancer_KLK2 comPAS_78278343PCR3001' on Oct. 3.

Study Type: Interventional

Study Design: Interventional double blind randomized placebo controlled trial (Safety, Efficacy)

Primary Sponsor: Janssen-Cilag International NV

Condition: Metastatic Castration-resistant Prostate Cancer Cancer

Intervention: Arm 1: Pasritamig with Best Supportive Care (BSC) Participants in this arm recei...